WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation’s (Nasdaq: OSCI) fluoroquinolone antibiotic, FACTIVE® (gemifloxacin mesylate) tablets, is recommended, among other fluoroquinolones, for the treatment of patients with co-morbidities in the latest community-acquired pneumonia (CAP) consensus guidelines from the Infectious Diseases Society of American (IDSA) and the American Thoracic Society (ATS). Appearing as a supplement in the March 2007 issue of Clinical Infectious Diseases, the guidelines, titled “Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines in the Management of Community-Acquired Pneumonia in Adults,” outline the recommendations for treating CAP under several different conditions.
